Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.65) per share.
Raymond James Maintains Outperform on bluebird bio, Raises Price Target to $10
Raymond James analyst Dane Leone maintains bluebird bio (NASDAQ:BLUE) with a Outperform and raises the price target from $8 to $10.